Genetic and Clinical Determinants of Chronic Thromboembolic Pulmonary Hypertension: The Role of PAI-1 Polymorphism
International Journal of Molecular Sciences · 2026
DOI: 10.3390/ijms27020758 ↗Kurz gefasst
Fachartikel in der Zeitschrift International Journal of Molecular Sciences, 2026. Verfasst von Özgür Batum und 7 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pulmonology, University of Health Sciences Turkiye, Izmir Faculty of Medicine, Izmir City Hospital, Izmir 35540, Turkey. Hauptthemen laut MEDLINE: Plasminogen Activator Inhibitor 1, Hypertension, Pulmonary, Pulmonary Embolism, Polymorphism, Genetic. Die Arbeit nennt 32 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Chronic thromboembolic pulmonary disease (CTEPD) is a severe long-term complication of acute pulmonary thromboembolism (PTE). Its pathogenesis is multifactorial, involving incomplete thrombus resolution, hemodynamic burden, comorbidities, and genetic factors. However, the contribution of inherited thrombophilic mutations to CTEPD development remains controversial. This retrospective cohort study included 204 patients diagnosed with acute PTE at a tertiary referral center between December 2023 and December 2024. Baseline demographic, clinical, laboratory, and echocardiographic data were collected. Genetic analysis assessed Factor II, Factor V Leiden, MTHFR C677T, MTHFR A1298C, Factor XIII V34L, and PAI-1 4G/5G polymorphisms. Patients were followed for at least 12 months for the development of CTEPD, defined according to guideline-based hemodynamic and imaging criteria. During follow-up, 17 patients (8.3%) developed CTEPD. Patients with CTEPD were significantly older and had higher baseline and follow-up systolic pulmonary artery pressure (sPAP) (p < 0.001), elevated NT-proBNP and troponin levels (both p < 0.001), and more frequent comorbidities, including cardiac and renal disease. Multivariate logistic regression identified comorbid diseases (HR: 0.17, 95% CI: 0.039–0.80, p = 0.025) and genetic thrombophilic factors (HR: 0.30, 95% CI: 0.10–0.91, p = 0.034) as independent predictors. Among genetic variants, only the PAI-1 4G/5G polymorphism was significantly associated with CTEPD (p = 0.001). Our study demonstrates that advanced age, comorbid diseases, elevated cardiac biomarkers, and genetic predisposition are associated with the development of CTEPD after acute PTE, while the PAI-1 4G/5G polymorphism may contribute to CTEPD susceptibility within a multifactorial context.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Pulmonology, University of Health Sciences Turkiye, Izmir Faculty of Medicine, Izmir City Hospital, Izmir 35540, Turkey.
- Department of Medical Genetics, University of Health Sciences Turkiye, Izmir Faculty of Medicine, Izmir City Hospital, Izmir 35540, Turkey.
- Department of Pulmonology, University of Health Sciences, Izmir City Hospital, Izmir 35540, Turkey.
ORCID-Profile: Özgür Batum, Merve Ayık Türk, Yelda Varol, Berk Özyılmaz, Alp Eren Akarçay, Nigar Dirican, Sibel Doruk, Sami Deniz
Zitieren
APA
Batum, Ö., Ayık Türk, M., Varol, Y., Özyılmaz, B., Akarçay, A. E., Dirican, N., Doruk, S., & Deniz, S. (2026). Genetic and Clinical Determinants of Chronic Thromboembolic Pulmonary Hypertension: The Role of PAI-1 Polymorphism. International Journal of Molecular Sciences. https://doi.org/10.3390/ijms27020758
Vancouver
Batum Ö, Ayık Türk M, Varol Y, Özyılmaz B, Akarçay AE, Dirican N, et al. Genetic and Clinical Determinants of Chronic Thromboembolic Pulmonary Hypertension: The Role of PAI-1 Polymorphism. International Journal of Molecular Sciences. 2026. doi:10.3390/ijms27020758
BibTeX
@article{Batum2026,
author = {Batum, Özgür and Ayık Türk, Merve and Varol, Yelda and Özyılmaz, Berk and Akarçay, Alp Eren and Dirican, Nigar and Doruk, Sibel and Deniz, Sami},
title = {Genetic and Clinical Determinants of Chronic Thromboembolic Pulmonary Hypertension: The Role of PAI-1 Polymorphism},
journal = {International Journal of Molecular Sciences},
year = {2026},
doi = {10.3390/ijms27020758}
}
EUVIMED